The metabolic abnormalities associated with non-alcoholic fatty liver disease

被引:108
作者
Haque, M
Sanyal, AJ
机构
[1] Virginia Commonwealth Univ, Dept Internal Med, Div Gastroenterol, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Dept Internal Med, Div Hepatol & Nutr, Richmond, VA 23298 USA
关键词
insulin resistance; syndrome-X; fatty liver; fatty liver disease; steatohepatitis; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; oxidant stress; lipid metabolism;
D O I
10.1053/bega.2002.0325
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) is a common disorder in the Western hemisphere. It encompasses two histological lesions: fatty liver and steatohepatitis. A large body of literature indicates that insulin resistance is a key pathophysiological abnormality in patients with NAFLD. Insulin resistance results from a complex interplay between the major targets of insulin action, i.e. muscle, adipose tissue and liver, versus the ability of the pancreatic islet 0 cells to compensate for insulin resistance by increasing insulin production. The metabolic and clinical profile associated with insulin resistance is thus defined by the factors that produce and maintain insulin resistance and the effects of decreased insulin sensitivity on various insulin-dependent pathways. The major metabolic defects associated with insulin resistance are increased peripheral lipolysis, increased hepatic glucose output due to increased gluconeogenesis and increased lipid oxidation. This is associated with an oxidative stress in the liver that may be compounded by additional pathophysiological abnormalities. While much work remains to be done, the current understanding of the pathogenesis of NAFLD provides direction for both future investigation and development of therapeutic trials.
引用
收藏
页码:709 / 731
页数:23
相关论文
共 118 条
[1]   Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha [J].
Alessi, DR ;
James, SR ;
Downes, CP ;
Holmes, AB ;
Gaffney, PRJ ;
Reese, CB ;
Cohen, P .
CURRENT BIOLOGY, 1997, 7 (04) :261-269
[2]   Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro [J].
Anthonsen, MW ;
Rönnstrand, L ;
Wernstedt, C ;
Degerman, E ;
Holm, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (01) :215-221
[3]   ALTERNATIVE PATHWAY OF INSULIN SIGNALING IN MICE WITH TARGETED DISRUPTION OF THE IRS-1 GENE [J].
ARAKI, E ;
LIPES, MA ;
PATTI, ME ;
BRUNING, JC ;
HAAG, B ;
JOHNSON, RS ;
KAHN, CR .
NATURE, 1994, 372 (6502) :186-190
[4]   NONALCOHOLIC STEATOHEPATITIS - AN EXPANDED CLINICAL ENTITY [J].
BACON, BR ;
FARAHVASH, MJ ;
JANNEY, CG ;
NEUSCHWANDERTETRI, BA .
GASTROENTEROLOGY, 1994, 107 (04) :1103-1109
[5]  
Bailey JL, 2000, J NEPHROL, V13, P89
[6]   CAP defines a second signalling pathway required for insulin-stimulated glucose transport [J].
Baumann, CA ;
Ribon, V ;
Kanzaki, M ;
Thurmond, DC ;
Mora, S ;
Shigematsu, S ;
Bickel, PE ;
Pessin, JE ;
Saltiel, AR .
NATURE, 2000, 407 (6801) :202-207
[7]   INSULIN DECREASES H4IIE CELL PEPCK MESSENGER-RNA BY A MECHANISM THAT DOES NOT INVOLVE CAMP [J].
BEALE, EG ;
KOCH, SR ;
BROTHERTON, AFA ;
SHEORAIN, VS ;
GRANNER, DK .
DIABETES, 1986, 35 (05) :546-549
[8]   Prevalence of and risk factors for hepatic steatosis in northern Italy [J].
Bellentani, S ;
Saccoccio, G ;
Masutti, F ;
Crocè, LS ;
Brandi, G ;
Sasso, F ;
Cristanini, G ;
Tiribelli, C .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (02) :112-117
[9]   QUANTITATIVE ESTIMATION OF INSULIN SENSITIVITY [J].
BERGMAN, RN ;
IDER, YZ ;
BOWDEN, CR ;
COBELLI, C .
AMERICAN JOURNAL OF PHYSIOLOGY, 1979, 236 (06) :E667-E677
[10]  
Bergman RN, 1997, RECENT PROG HORM RES, V52, P359